LATEST ALERTS
The CBD regulatory tracker offers a deep analysis of the regulations and proposals in over 50 countries, for nine major regulatory areas: hemp cultivation, processing, flower, extracts, food, cosmetics, vaping, pet food and import/export
Nearly eight years after the legalisation of medical cannabis in Australia, most people who use it to treat a health condition obtain it legally, through a doctor’s prescription
The recent discovery of the illicit animal tranquilliser xylazine in cannabis vapes raises concerns about harmful contaminants. How do these substances end up in vaping products?
In this part of a series of articles celebrating the tenth anniversary of Tamarind Intelligence, we look at how the landscape of intoxicating hemp-derived cannabinoids (IHDCs) across Europe has changed over the years
An expert panel report that could set the stage for changes in coming months in the way cannabis is bought, sold and marketed across Canada is recommending wide-ranging amendments to the country’s cannabis law
Shortly after drafting its first proposal on cannabis regulation, the Czech government has banned semi-synthetic cannabinoids HHC, HHC acetate (HHC-O) and tetrahydrocannabiforol (THCP)
Cannabinoids can be found in numerous plants, animals and fungi, and as more are unearthed and their properties tested, our knowledge of potential applications and uses expands
Young US adults are more likely to use cannabis than to vape or smoke cigarettes, says a new Gallup poll, and concerns about cannabis use are not comparable to fears around vaping and smoking
The US Federal Trade Commission and Food and Drug Administration have sent warning letters to six sellers of delta-8 THC edibles whose packaging is very similar to that of popular snacks and sweets for children
US cannabis users are three times more likely to be cigarette smokers than those who don’t use cannabis, but this statistic is an example of the “gateway drug fallacy”
This report provides an overview of the current regulatory framework in place in South Africa for hemp, CBD and other cannabinoids, as well as medical and recreational cannabis
Researchers at the US Food and Drug Administration (FDA) recently published a review on the toxicity of orally-consumed CBD, largely echoing worries outlined in other safety reviews. So how worried should we be?
Kombinat Konopny CEO and founder Maciej Kowalski talks to podcast host Oliver Prescott about the company’s win in Poland’s high court, subsequent changes in the industry and current cannabis food policy in Europe
A new study of the relationship between opioids and cannabis via payments to doctors in US states offers little towards understanding the potential of cannabis as a substitute for opioids
While statistics are vital to understanding our world, they are often misunderstood – and that can be important when it comes to forming opinions and laws on controversial issues such as cannabis
Comments by the chair of the UK Committee on Toxicity (COT) about reactions to CBD have stirred up a hornet’s nest – but the furore suggests a misunderstanding of what he actually said
Kanavape founder Sebastien Beguerie talks with CannIntelligence podcast host Tiziana Cauli about his judicial battle leading to a crucial European Court of Justice ruling which established CBD legal status across Europe
Cannabis companies are looking to get Google certification as part of the tech giant’s update on the use of Google Ads for CBD products in parts of the US
The US Food and Drug Administration (FDA) has issued a final guidance document for the development of medical drugs containing cannabis
CBD company Chanelle McCoy Health has received approval to start a trial which may allow it to sell its CBD sleeping aid as an over-the-counter (OTC) drug in Australian pharmacies
The recreational reputation of synthetic cannabinoids – synthetic cannabinoid receptor agonists (SCRAs) – precedes them, leading to restrictions on use and even research
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
